A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor

NCT07000344 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Results failed to achieve the anticipated effect.

Conditions

Ovarian Cancer

Interventions

DRUG: Cohort 1 (triple-drug group)
DRUG: Cohort 2 (dual-drug group)

Sponsor

Peking Union Medical College Hospital